SLXN:US
$0.946
2.637%
Silexion Therapeutics CorpNews & Events
Last updated: Jun 7, 2025, 12:00 PM ET
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers
GlobeNewswire MAY 29, 2025 9:05 AM EDTGRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDA...READ ARTICLESilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer
GlobeNewswire MAY 21, 2025 8:45 AM EDTGRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ...READ ARTICLESilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire MAY 13, 2025 4:45 PM EDTGRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDA...READ ARTICLESilexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
GlobeNewswire APR 23, 2025 9:20 AM EDTGrand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NAS...READ ARTICLESilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
GlobeNewswire MAR 28, 2025 8:30 AM EDTGrand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NAS...READ ARTICLESilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
GlobeNewswire MAR 21, 2025 8:30 AM EDTGrand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (&#x...READ ARTICLESilexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire MAR 18, 2025 4:29 PM EDTGrand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NAS...READ ARTICLEPESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis - Signaling a Potential Paradigm Shift in Cancer Treatment
Business Wire MAR 17, 2025 8:15 AM EDTSilexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Pl...READ ARTICLESilexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
GlobeNewswire MAR 5, 2025 8:30 AM ESTGrand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NAS...READ ARTICLEPESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
Business Wire MAR 3, 2025 8:30 AM ESTSilexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic ca...READ ARTICLE